Vanda's eczema drug fails mid-stage study, shares fall

March 4, 2015 10:00 PM

2 0

Atopic dermatitis or eczema is a chronic skin rash or inflammation that often appears in infancy. It affects between 9 and 30 percent of the U.S. population, according to the National Institutes of Health. The cause of the disease is unknown.

The study data showed no statistical difference between patients on the drug, tradipitant, and those on a placebo, due to a "very high placebo effect", the company said on Wednesday.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page